|Articles|June 1, 2007

GENERIC BOOM FORECAST FOR 2011-2012

Brand name prescription drugs with annual sales of >$140 billion are in line to lose patent protection between now and 2016, according to a new analysis that bodes well for the generic pharmaceutical industry?s prospects during the coming decade. The analysis by researchers at Data-monitor predicts that the peak of the patent expirations will occur during 2011 and 2012, when heavily prescribed branded products such as clopi-dogrel bisulfate (Plavix), atorvas-tatin calcium (Lipitor), fluticasone propionate and salmeterol inhalation powder (Advair), and queti-apine fumarate (Seroquel) will face generic competition for the first time.

Articles in this issue

over 18 years ago

Article

otc Product News

over 18 years ago

Article

case STUDIES

over 18 years ago

Article

can you READ these Rxs?

over 18 years ago

Article

compounding HOTLINE

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Latest CME